1100P Anti-PD1 + low-dose anti-CTLA4 immunotherapy pathological response rate in patients with stage III resectable melanoma: Phase III NEOMIMAJOR trial interim analysis
Authors:
- I.V. SamoylenkoISI.V. Samoylenko
- L. DemidovLDL. Demidov
- S. DziamidavaSDS. Dziamidava
- A. ZiminaAZA. Zimina
- V. KozlovVKV. Kozlov
- S. OdintsovaSOS. Odintsova
- I. ShumskayaISI. Shumskaya
- N. FadeevaNFN. Fadeeva
- I. UtyashevIUI. Utyashev
- K.D. PenkovKPK.D. Penkov
- D. StroyakovskiyDSD. Stroyakovskiy
- D. KirtbayaDKD. Kirtbaya
- 17 September 2024
- journal article
- Published by Elsevier in Annals of Oncology
- Vol. 35, S729